These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32774500)

  • 21.
    Liu YL; Selenica P; Zhou Q; Iasonos A; Callahan M; Feit NZ; Boland J; Vazquez-Garcia I; Mandelker D; Zehir A; Burger RA; Powell DJ; Friedman C; Cadoo K; Grisham R; Konner JA; O'Cearbhaill RE; Aghajanian C; Reis-Filho JS; Weigelt B; Zamarin D
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
    Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
    Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endometrial cancer risk and survival by tumor MMR status.
    Nagle CM; O'Mara TA; Tan Y; Buchanan DD; Obermair A; Blomfield P; Quinn MA; Webb PM; Spurdle AB;
    J Gynecol Oncol; 2018 May; 29(3):e39. PubMed ID: 29533022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression.
    Mäki-Nevala S; Valo S; Ristimäki A; Sarhadi V; Knuutila S; Nyström M; Renkonen-Sinisalo L; Lepistö A; Mecklin JP; Peltomäki P
    EBioMedicine; 2019 Jan; 39():280-291. PubMed ID: 30578081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study.
    Sun S; Liu Y; Eisfeld AK; Zhen F; Jin S; Gao W; Yu T; Chen L; Wang W; Chen W; Yuan M; Chen R; He K; Guo R
    Front Oncol; 2019; 9():550. PubMed ID: 31297337
    [No Abstract]   [Full Text] [Related]  

  • 29. Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
    Lin AY; Lin E
    J Hematol Oncol; 2015 Nov; 8():124. PubMed ID: 26542241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel.
    Zhuang W; Ma J; Chen X; Wang G; Lu J; Chen Y; Dong H; Cai S; Zhang Y; Zhao X; Zhu Y; Xu C; Huang Y; Huang Z; Zhu X; Jiang H; Wang Z
    J Cancer; 2018; 9(13):2302-2307. PubMed ID: 30026825
    [No Abstract]   [Full Text] [Related]  

  • 31. Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.
    Xu J; Bao H; Wu X; Wang X; Shao YW; Sun T
    Oncol Lett; 2019 Jul; 18(1):449-455. PubMed ID: 31289516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Somatic Mutational Landscape of Mismatch Repair Deficient Prostate Cancer.
    Fang B; Wei Y; Pan J; Zhang T; Ye D; Zhu Y
    J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review.
    Xie T; Feng Q; Li Z; Lu M; Li J; Lizaso A; Xiang J; Zhang L; Shen L; Peng Z
    Hered Cancer Clin Pract; 2021 Jan; 19(1):7. PubMed ID: 33422121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.
    Patel SA; Longacre TA; Ladabaum U; Lebensohn A; Lin AY; Haraldsdottir S
    Oncologist; 2018 Dec; 23(12):1395-1400. PubMed ID: 30072391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome.
    Courtet K; Laizet Y; Lucchesi C; Bessede A; Italiano A
    Biomark Res; 2020; 8():26. PubMed ID: 32695398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.
    Takamochi K; Takahashi F; Suehara Y; Sato E; Kohsaka S; Hayashi T; Kitano S; Uneno T; Kojima S; Takeuchi K; Mano H; Suzuki K
    Lung Cancer; 2017 Aug; 110():26-31. PubMed ID: 28676214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
    Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
    Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.
    Usuda K; Niida Y; Iwai S; Funasaki A; Sekimura A; Motono N; Yamada S; Uramoto H
    Front Oncol; 2020; 10():689. PubMed ID: 32582526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.